GSK’s Shingrix Vaccine Can Reach Millions More

US FDA Clears New Claim In Immunocompromised Adults

The shingles vaccine could potentially be used in about three million immunocompromised people, according to GSK, but CDC’s advisory committee will weigh in with recommendations.

Shingles vaccine
US FDA approves Shingrix for use in immunocompromised adults • Source: Alamy

GlaxoSmithKline plc stands to significantly expand the market opportunity for its blockbuster shingles vaccine Shingrix (zoster vaccine recombinant, adjuvanted) with a new approval by the US Food and Drug Administration for prevention of shingles (herpes zoster) use in immunocompromised adults.

The company said that the indication could reach 3 million more people based on the populations it studied, but the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip